Intracranial injection of NK cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.

Michael C BurgerMarie-Therese ForsterAnnette RomanskiFlorian StraßheimerJadranka MacasPia S ZeinerEike SteidlStefanie HerktKatharina J WeberJonathan SchuppJennifer H LunMaja I StreckerKarolin WlotzkaPinar CakmakCorinna OpitzRosemol GeorgeIris C MildenbergerPaulina NowakowskaCongcong ZhangJasmin RöderElvira MüllerKristina IhrigKarl-Josef LangenMichael A RiegerEva HerrmannHalvard BönigPatrick N HarterYvonne ReissElke HattingenFranz RödelKarl H PlateTorsten TonnChristian SenftJoachim P SteinbachWinfried S Wels

Published in: Neuro-oncology (2023)

Intracranial injection of HER2-targeted CAR-NK cells is feasible and safe in patients with recurrent GB. 1 x 10 8 NK-92/5.28.z cells was determined as the maximum feasible dose for a subsequent expansion cohort with repetitive local injections of CAR-NK cells.

Keyphrases

nk cells
ultrasound guided
induced apoptosis
cancer therapy
cell cycle arrest
optic nerve
high frequency
cell death
signaling pathway
drug delivery
endoplasmic reticulum stress
cell proliferation